11-13 which were previously considered to be safe in patients with kidney disease. 14 In an upcoming report, Todd et al demonstrate that 24-month mortality is increased in outpatient hemodialysis patients with the cutaneous changes of NSF (48% versus 21%), with an adjusted hazard ratio of 2.9 (95% CI, 1. 4-5.9. 15
